WO2022236176A3 - Fxa protein for treating and/or preventing covid-19 - Google Patents

Fxa protein for treating and/or preventing covid-19 Download PDF

Info

Publication number
WO2022236176A3
WO2022236176A3 PCT/US2022/028358 US2022028358W WO2022236176A3 WO 2022236176 A3 WO2022236176 A3 WO 2022236176A3 US 2022028358 W US2022028358 W US 2022028358W WO 2022236176 A3 WO2022236176 A3 WO 2022236176A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
fxa
fxa protein
preventing covid
covid
Prior art date
Application number
PCT/US2022/028358
Other languages
French (fr)
Other versions
WO2022236176A2 (en
Inventor
Jianhua Yu
Michael A. Caligiuri
Original Assignee
City Of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City Of Hope filed Critical City Of Hope
Publication of WO2022236176A2 publication Critical patent/WO2022236176A2/en
Publication of WO2022236176A3 publication Critical patent/WO2022236176A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)

Abstract

Provided herein are, inter alia, methods and compositions useful for treating or preventing COVID-19 in a subject in need thereof. The compositions include Factor Xa (FXa) protein or functional portion thereof. The compositions may further include an anticoagulant, particularly an indirect inhibitor of FXa.
PCT/US2022/028358 2021-05-07 2022-05-09 Fxa protein for treating and/or preventing covid-19 WO2022236176A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163186042P 2021-05-07 2021-05-07
US63/186,042 2021-05-07

Publications (2)

Publication Number Publication Date
WO2022236176A2 WO2022236176A2 (en) 2022-11-10
WO2022236176A3 true WO2022236176A3 (en) 2022-12-22

Family

ID=83933040

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2022/028358 WO2022236176A2 (en) 2021-05-07 2022-05-09 Fxa protein for treating and/or preventing covid-19

Country Status (1)

Country Link
WO (1) WO2022236176A2 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110236474A1 (en) * 2010-03-26 2011-09-29 Leonard Thomas W Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration
US20120244139A1 (en) * 2005-10-21 2012-09-27 Madison Edwin L Modified proteases that inhibit complement activation
US20190309279A1 (en) * 2007-09-28 2019-10-10 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
WO2020079155A1 (en) * 2018-10-17 2020-04-23 Enzyre B.V. Novel chemiluminescent substrates for factor xa

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120244139A1 (en) * 2005-10-21 2012-09-27 Madison Edwin L Modified proteases that inhibit complement activation
US20190309279A1 (en) * 2007-09-28 2019-10-10 Portola Pharmaceuticals, Inc. Antidotes for factor xa inhibitors and methods of using the same
US20110236474A1 (en) * 2010-03-26 2011-09-29 Leonard Thomas W Pharmaceutical Compositions of Selective Factor Xa Inhibitors for Oral Administration
WO2020079155A1 (en) * 2018-10-17 2020-04-23 Enzyre B.V. Novel chemiluminescent substrates for factor xa

Also Published As

Publication number Publication date
WO2022236176A2 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
BR0214992A (en) Hydrophilic microfibrillated article, and method for preparing the same
EA200600602A1 (en) SYNERGISTIC FUNGICIDE COMBINATIONS OF BIOLOGICALLY ACTIVE SUBSTANCES
RS51903B (en) Aripiprazole complex formulation and method
WO2001098317A3 (en) Alpha-glycosylceramides for treating bacterial and fungal infections
NO20053470L (en) Triazolopyridazines as protein kinase inhibitors
WO2004080425A3 (en) Polypeptide compounds for inhibiting angiogenesis and tumor growth
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
MXPA04001523A (en) Rapamycin dialdehydes.
UA88463C2 (en) Pharmaceutical composition comprising compound i and method of treating hiv infection
WO2007053685A3 (en) Methods of treating atrial fibrillation with p38 inhibitor compounds
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
WO2004039248A3 (en) Repairing or replacing tissues or organs
WO2004014351A3 (en) Use of cgrp antagonist compounds for treatment of psoriasis
WO2004030622A3 (en) Method of isolation and self-assembly of small protein particles from blood and other biological materials
HRP20080413T3 (en) Medicament for the treatment of fungal infections, particularly aspergillosis
WO2004113278A3 (en) Acylsulfamide inhibitors of factor viia
WO2004049907A3 (en) Compositions and methods for treating transplants
WO2003039491A8 (en) Novel isoforms of vascular endothelial cell growth inhibitor
ATE397861T1 (en) SYNERGISTIC COMPOSITIONS
WO2004009773A3 (en) Methods and compositions for activating or inhibiting vegf-d and vegf-c
WO2004091436A3 (en) Methods and compositions for treating ocular disease
WO2022236176A3 (en) Fxa protein for treating and/or preventing covid-19
WO2003047517A3 (en) Novel-n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-(trifluoromethyl)-1-h-pyrazole-5-carboxamides as factor xa
WO2021203016A3 (en) Protein-protein interaction stabilizers
WO2005019269A3 (en) Techniques and compositions for the diagnosis and treatment of cancer (muc1)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE